ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,018.39
      -0.34%
      US Tech 100
      0.00
      0.00%
      Dow Jones
      37,903.29
      0.23%
      Brent Oil
      84.155
      0.74%
      Bitcoin
      57,730.05
      -0.87%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Cogent Biosciences Inc (COGT)

      7. Cogent Biosciences Inc (COGT) News

      COGT

      Cogent Biosciences (COGT)

      Cogent Biosciences Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:COGT
      DateTimeSourceHeadlineSymbolCompany
      04/09/20249:00AMGlobeNewswire Inc.Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorNASDAQ:COGTCogent Biosciences Inc
      02/26/20244:34PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:COGTCogent Biosciences Inc
      02/26/20249:13AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:COGTCogent Biosciences Inc
      02/26/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
      02/26/20248:00AMGlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
      02/22/20242:30PMGlobeNewswire Inc.Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisNASDAQ:COGTCogent Biosciences Inc
      02/16/20246:55PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:COGTCogent Biosciences Inc
      02/16/20246:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
      02/14/20244:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COGTCogent Biosciences Inc
      02/14/202412:51PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:COGTCogent Biosciences Inc
      02/14/20248:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
      02/14/20247:00AMGlobeNewswire Inc.Cogent Biosciences Announces Oversubscribed $225 Million Private PlacementNASDAQ:COGTCogent Biosciences Inc
      02/09/20244:22PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COGTCogent Biosciences Inc
      02/05/20249:00AMGlobeNewswire Inc.Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual MeetingNASDAQ:COGTCogent Biosciences Inc
      01/25/20244:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
      01/25/20244:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
      01/25/20244:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
      01/25/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
      01/09/20248:00AMGlobeNewswire Inc.Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted TherapeuticsNASDAQ:COGTCogent Biosciences Inc
      01/04/20244:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COGTCogent Biosciences Inc
      01/02/20248:00AMGlobeNewswire Inc.Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:COGTCogent Biosciences Inc
      12/11/20238:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
      12/11/20237:55AMGlobeNewswire Inc.Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)NASDAQ:COGTCogent Biosciences Inc
      12/09/20231:30PMGlobeNewswire Inc.Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)NASDAQ:COGTCogent Biosciences Inc
      12/07/20239:00AMGlobeNewswire Inc.Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer SymposiumNASDAQ:COGTCogent Biosciences Inc
      12/04/20238:00AMGlobeNewswire Inc.Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual MeetingNASDAQ:COGTCogent Biosciences Inc
      11/29/20238:00AMGlobeNewswire Inc.Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer SymposiumNASDAQ:COGTCogent Biosciences Inc
      11/07/20237:27AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COGTCogent Biosciences Inc
      11/02/20239:18AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COGTCogent Biosciences Inc
      11/02/20239:00AMGlobeNewswire Inc.Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsNASDAQ:COGTCogent Biosciences Inc
       Showing the most relevant articles for your search:NASDAQ:COGT